CD4 and neoplasm: Moreover, in ICOS- or ICOS ligand (ICOSL)-deficient mice, the efficacy of anti–CTLA-4 therapy was significantly diminished, although the specific contribution of ICOS+CD4+ cells versus ICOS+CD8+ cells in tumor rejection was not addressed in this study (78).